Pfizer begins process to achieve full approval of its COVID-19 vaccine

Pfizer begins process to achieve full approval of its COVID-19 vaccine

Pfizer and BionNTech began the application process for full approval of their COVID-19 vaccine with the US Food and Drug Administration (FDA).

The vaccine has had an emergency approval since last December 11. Both companies say that since then some 170 million doses have been distributed in the United States.

In a statement released Friday, Pfizer CEO Albert Bourla highlighted progress in vaccination with his product since its emergency approval.

“We are proud of the tremendous progress we have made since December, distributing vaccines to millions of Americans,” the executive said.

PFIZDR VACCINE HAS EMERGENCY APPROVAL

“We look forward to working with the FDA to complete the submission process and support its review, with the goal of achieving final approval of the vaccine in the coming months.”

Emergency approval granted the use of the vaccine conditionally.

Biden’s announcement was greeted with sharp falls in the shares of the pharmaceutical companies Pfizer and BioNTech, as well as Moderna and Novavax on the Wall Street stock market.

So far, more than 250,00,000 million doses have been applied in the US, of which, more than 134,00,000 vaccines are from Pfizer.

Melissa Galbraith
Melissa Galbraith is the World News reporter for Globe Live Media. She covers all the major events happening around the World. From Europe to Americas, from Asia to Antarctica, Melissa covers it all. Never miss another Major World Event by bookmarking her author page right here.